论文部分内容阅读
Objective:The radioprotective effects of amifostine remain uncertain in patents with nasopharyngeal carcinoma (NPC),and adverse effects and cost limit generalization of its classical everyday regimen.This phase Ⅱ multicenter randomized controlled trial aimed to explore whether amifostine could ameliorate the toxicities of NPC patients in the era of intensity-modulated radiotherapy (IMRT),and to compare different regimens of amifostine on effectiveness and safety.Methods:Patients with stage Ⅰ-ⅣB NPC were involved prospectively from January 1st,2013.All patients received radical treatment based on IMRT.After a randomization stratified by their stage,these patients were allocated into 3 groups:the group treated without amifostine,the group treated with the everyday regimen of amifostine,and the group treated with the every-other-day regimen.The 3 groups of patients were compared on radiotherapy-related acute toxicities,treatment effects of NPC,and amifostine-related complications.This trial was registered on the clinicaltrials.gov (ID:NCT01762514).Results:Until August 31st,2017,totally 187 patents completed experimental intervention.Only amifostine of everyday regimen appeared to reduce the patient proportion of mucositis (79.1％ vs.96.8％,P=0.002).Hypocalcemia was less common in patients treated without amifostine than in those treated with amifostine (22.6％ vs.53.4％ vs.41.8％,P=0.002).Neither complete remission rates nor the survivals were affected by amifostine.Conclusions:Amifostine of everyday regimen could reduce mucositis in NPC patients who received IMRT,though it also had the possibility to cause more hypocalcemia.